ISSN:
1432-0584
Keywords:
MDS
;
Cytokine
;
G-CSF
;
EPO
;
Combination therapy
Source:
Springer Online Journal Archives 1860-2000
Topics:
Medicine
Notes:
Summary Recombinant human granulocyte colonystimulating factor (rhG-CSF) and erythropoietin (rhE-PO) were used to treat ten patients with myelodysplastic syndromes (MDS). None of the patients showed a favorable response in erythrocyte and platelet counts following 10 weeks' treatment, although favorable responses in neutrophil counts were observed in eight of ten patients (80.0%) and in seven of eight patients (87.5%) following 2 weeks' and 10 weeks' treatment, respectively. However, one patient with refractory anemia had a delayed favorable response in erythrocyte and neutrophil counts at week 14 in spite of the cessation of combination therapy at week 10. These results indicate that combination therapy with rhG-CSF and rhEPO is not beneficial to patients with MDS, based on the presently used protocol.
Type of Medium:
Electronic Resource
URL:
http://dx.doi.org/10.1007/BF01834360
Permalink